Eli Lilly And Company's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 3.71, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Eli Lilly in Mar 31 2026 quarter, has decreased to 98 days, compared to 99 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 452 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 1541 to 3046.

What is Receivable Turnover Ratio?
What is Eli Lilly And Company Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LLY Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	51.23 %	51.82 %	61.45 %	31.55 %	39.84 %
Y / Y Revenue Change	55.55 %	42.56 %	53.87 %	37.64 %	45.17 %
Receivable Turnover Ratio (TTM)	3.71	3.68	3.72	3.77	3.74
LLY's Total Ranking	# 3046	# 1541	# 2874	# 2745	# 2941
Accounts Receivable average collection period days	99	99	98	97	98
Seq. Receivable Change	5.07 %	3.59 %	13.09 %	22.87 %	5.48 %
Seq. Revenue Change	2.63 %	9.61 %	13.13 %	22.23 %	-5.94 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 139
Healthcare Sector	# 453
Overall Market	# 3046

Receivable Turnover Ratio Statistics
High	Average	Low
6.89	5.12	3.3
(Dec 31 2013)		(Mar 31 2023)

LLY Company Profile • Back to LLY Efficiency Comparisons • Compare LLY Receivables Turnover Ratio to its Competitors

Financial Statements
Eli Lilly's Accounts Receivable	$ 21,177 Millions	Visit LLY's Balance sheet
Eli Lilly's Sales TTM	$ 72,250 Millions	Visit LLY's Income Statement
Sources of LLY's Revenues		Visit LLY's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
LLY's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
LLY's Growth Rates	LLY's Roa	LLY's Inventory Turnover Ratio	LLY's Dividend Comparisons
LLY's Profitability Ratios	LLY's Roi	LLY's Asset Turnover Ratio	LLY's Dividend Growth
LLY's Valuation Ratios	LLY's Roe	LLY's Financial Strength Ratios	LLY's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Tandem Diabetes Care Inc	9.34	$ 1,023.420 Millions	$ 109.550 Millions
Sunshine Biopharma Inc	9.33	$ 35.493 Millions	$ 3.804 Millions
The Oncology Institute Inc	9.30	$ 545.764 Millions	$ 58.671 Millions
The Pennant Group Inc	9.28	$ 1,023.227 Millions	$ 110.305 Millions
Volitionrx Limited	9.23	$ 2.466 Millions	$ 0.267 Millions
Lucid Diagnostics Inc	9.11	$ 5.134 Millions	$ 0.564 Millions
Soleno Therapeutics Inc	9.09	$ 285.008 Millions	$ 31.369 Millions
Zomedica Corp	9.07	$ 34.660 Millions	$ 3.820 Millions
Dariohealth Corp	9.03	$ 20.983 Millions	$ 2.324 Millions
Harmony Biosciences Holdings inc	9.02	$ 899.247 Millions	$ 99.660 Millions
Tactile Systems Technology Inc	9.01	$ 343.414 Millions	$ 38.110 Millions
Ardent Health Inc	8.99	$ 6,428.975 Millions	$ 715.036 Millions
Sanuwave Health Inc	8.91	$ 44.328 Millions	$ 4.973 Millions
Biocryst Pharmaceuticals Inc	8.89	$ 885.716 Millions	$ 99.648 Millions
Madrigal Pharmaceuticals Inc	8.81	$ 1,132.490 Millions	$ 128.587 Millions
Inogen Inc	8.80	$ 351.497 Millions	$ 39.926 Millions
Enanta Pharmaceuticals Inc	8.78	$ 69.213 Millions	$ 7.879 Millions
Grail Inc	8.77	$ 156.120 Millions	$ 17.809 Millions
Eyepoint Inc	8.76	$ 7.614 Millions	$ 0.869 Millions
Scientific Industries Inc	8.65	$ 6.588 Millions	$ 0.761 Millions
Sanara Medtech Inc	8.60	$ 106.873 Millions	$ 12.423 Millions
Protalix Biotherapeutics inc	8.57	$ 76.381 Millions	$ 8.912 Millions
Adapthealth Corp	8.55	$ 3,286.774 Millions	$ 384.194 Millions
Perrigo Company Plc	8.52	$ 4,177.500 Millions	$ 490.200 Millions
Alpha Teknova Inc	8.48	$ 43.582 Millions	$ 5.141 Millions
Ensign Group Inc	8.47	$ 5,273.996 Millions	$ 622.757 Millions
Axogen inc	8.41	$ 238.105 Millions	$ 28.322 Millions
Tenet Healthcare Corp	8.40	$ 21,455.000 Millions	$ 2,555.250 Millions
Pediatrix Medical Group Inc	8.36	$ 1,931.686 Millions	$ 231.145 Millions
Alpha Pro Tech Ltd	8.32	$ 59.661 Millions	$ 7.167 Millions

Date modified: 2026-08-30T14:53:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.